These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31988038)

  • 1. Bone targeted delivery of salmon calcitonin hydroxyapatite nanoparticles for sublingual osteoporosis therapy (SLOT).
    Kotak DJ; Devarajan PV
    Nanomedicine; 2020 Feb; 24():102153. PubMed ID: 31988038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats.
    Bhandari KH; Newa M; Chapman J; Doschak MR
    J Control Release; 2012 Feb; 158(1):44-52. PubMed ID: 22001608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-loaded alginic acid nanoparticles for sublingual delivery.
    Patil NH; Devarajan PV
    Drug Deliv; 2016; 23(2):429-36. PubMed ID: 24901208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermolecular interactions between salmon calcitonin, hyaluronate, and chitosan and their impact on the process of formation and properties of peptide-loaded nanoparticles.
    Umerska A; Corrigan OI; Tajber L
    Int J Pharm; 2014 Dec; 477(1-2):102-12. PubMed ID: 25447822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis.
    Liu Y; Yu P; Peng X; Huang Q; Ding M; Chen Y; Jin R; Xie J; Zhao C; Li J
    J Control Release; 2019 Jun; 304():39-50. PubMed ID: 31054990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in bone properties by using risedronate adsorbed hydroxyapatite novel nanoparticle based formulation in a rat model of osteoporosis.
    Sahana H; Khajuria DK; Razdan R; Mahapatra DR; Bhat MR; Suresh S; Rao RR; Mariappan L
    J Biomed Nanotechnol; 2013 Feb; 9(2):193-201. PubMed ID: 23627045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of oral bioavailability of salmon calcitonin through chitosan-modified, dual drug-loaded nanoparticles.
    Liu L; Yang H; Lou Y; Wu JY; Miao J; Lu XY; Gao JQ
    Int J Pharm; 2019 Feb; 557():170-177. PubMed ID: 30597264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of combined salmon calcitonin and aspirin therapy for osteoporosis in ovariectomized rats.
    Wei J; Wang J; Gong Y; Zeng R
    Mol Med Rep; 2015 Aug; 12(2):1717-26. PubMed ID: 25891179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapeutic intervention for osteoporosis prepared with strontium hydroxyapatite and zoledronic acid: In vitro and pharmacodynamic evaluation.
    Khajuria DK; Vasireddi R; Trebbin M; Karasik D; Razdan R
    Mater Sci Eng C Mater Biol Appl; 2017 Feb; 71():698-708. PubMed ID: 27987763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and characterization of salmon calcitonin-sodium triphosphate ionic complex for oral delivery.
    Lee HE; Lee MJ; Park CR; Kim AY; Chun KH; Hwang HJ; Oh DH; Jeon SO; Kang JS; Jung TS; Choi GJ; Lee S
    J Control Release; 2010 Apr; 143(2):251-7. PubMed ID: 20026364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of reversible and nonreversible aqueous-soluble lipidized conjugates of salmon calcitonin.
    Cheng W; Lim LY
    Mol Pharm; 2008; 5(4):610-21. PubMed ID: 18481870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of bone targeting salmon calcitonin analogues in rats developing osteoporosis and adjuvant arthritis.
    Bhandari KH; Asghar W; Newa M; Jamali F; Doschak MR
    Curr Drug Deliv; 2015; 12(1):98-107. PubMed ID: 25860966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development, in vitro and in vivo characterization of zoledronic acid functionalized hydroxyapatite nanoparticle based formulation for treatment of osteoporosis in animal model.
    Khajuria DK; Razdan R; Mahapatra DR
    Eur J Pharm Sci; 2015 Jan; 66():173-83. PubMed ID: 25444840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversible lipidization for the oral delivery of salmon calcitonin.
    Wang J; Chow D; Heiati H; Shen WC
    J Control Release; 2003 Mar; 88(3):369-80. PubMed ID: 12644363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system.
    Wang H; Liu J; Tao S; Chai G; Wang J; Hu FQ; Yuan H
    Int J Nanomedicine; 2015; 10():5671-85. PubMed ID: 26388691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salmon Calcitonin Attenuates Degenerative Changes in Cartilage and Subchondral Bone in Lumbar Facet Joint in an Experimental Rat Model.
    Gou Y; Tian F; Kong Q; Chen T; Li H; Lv Q; Zhang L
    Med Sci Monit; 2018 May; 24():2849-2857. PubMed ID: 29748528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic evaluation of the calcitonin analogue SB 205614 in models of osteoclastic bone resorption in vitro and in vivo: comparison with salmon calcitonin and elcatonin.
    McSheehy PM; Farina C; Airaghi R; Allievi E; Banfi S; Bertolini D; Ferni G; Frattola D; Oneta S; Pinza M
    Bone; 1995 Apr; 16(4):435-44. PubMed ID: 7605704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of salmon calcitonin on experimental osteoporosis induced by ovariectomy and low-calcium diet in the rat.
    Mochizuki K; Inoue T
    J Bone Miner Metab; 2000; 18(4):194-207. PubMed ID: 10874598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-osteopenic effect of nasal salmon calcitonin in type 1 osteoporotic rats: comparison with subcutaneous dosing.
    Ichikawa M; Nakamuta H; Hoshino T; Ogawa Y; Koida M
    Biol Pharm Bull; 1994 Jul; 17(7):911-3. PubMed ID: 8000375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal effects of parathyroid hormone (1-34) in ovariectomized rats with or without concurrent administration of salmon calcitonin.
    DeLuca PP; Dani BA
    AAPS PharmSci; 2001; 3(4):E27. PubMed ID: 12049490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.